BriaCell Therapeutics Corp. Statistics
Share Statistics
BriaCell Therapeutics Corp. has 36.18M shares outstanding. The number of shares has increased by 92.16% in one year.
| Shares Outstanding | 36.18M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 67.95% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 32.51M |
| Failed to Deliver (FTD) Shares | 15.84K |
| FTD / Avg. Volume | 0.55% |
Short Selling Information
The latest short interest is 745.07K, so 2.06% of the outstanding shares have been sold short.
| Short Interest | 745.07K |
| Short % of Shares Out | 2.06% |
| Short % of Float | 2.29% |
| Short Ratio (days to cover) | 0.2 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -1.67.
| PE Ratio | 0 |
| Forward PE | -1.67 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | n/a |
Enterprise Valuation
BriaCell Therapeutics Corp. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 0.49, with a Debt / Equity ratio of 0.
| Current Ratio | 0.49 |
| Quick Ratio | 0.49 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is null% and return on capital (ROIC) is 1237.5%.
| Return on Equity (ROE) | null% |
| Return on Assets (ROA) | null% |
| Return on Capital (ROIC) | 1237.5% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -299.47K |
| Employee Count | 16 |
| Asset Turnover | null |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 62.85K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -84.02% in the last 52 weeks. The beta is 1.82, so BriaCell Therapeutics Corp.'s price volatility has been higher than the market average.
| Beta | 1.82 |
| 52-Week Price Change | -84.02% |
| 50-Day Moving Average | 0.84 |
| 200-Day Moving Average | 1.35 |
| Relative Strength Index (RSI) | 41.44 |
| Average Volume (20 Days) | 2.86M |
Income Statement
In the last 12 months, BriaCell Therapeutics Corp. had revenue of $0 and earned -$4.79M in profits. Earnings per share was $-0.29.
| Revenue | 0 |
| Gross Profit | -82.58K |
| Operating Income | -32.81M |
| Net Income | -4.79M |
| EBITDA | -4.77M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.29 |
Balance Sheet
The company has $862.09K in cash and $0 in debt, giving a net cash position of $862.09K.
| Cash & Cash Equivalents | 862.09K |
| Total Debt | 0 |
| Net Cash | 862.09K |
| Retained Earnings | -85.44M |
| Total Assets | 5.87M |
| Working Capital | -3.81M |
Cash Flow
In the last 12 months, operating cash flow was -$24.13M and capital expenditures -$456.80K, giving a free cash flow of -$24.58M.
| Operating Cash Flow | -24.13M |
| Capital Expenditures | -456.80K |
| Free Cash Flow | -24.58M |
| FCF Per Share | 0 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
BCTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -43.94% |
| FCF Yield | -102.23% |
Analyst Forecast
The average price target for BCTX is $15, which is 2172.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $15 |
| Price Target Difference | 2172.7% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Jan 2, 2020. It was a backward split with a ratio of 1:300.
| Last Split Date | Jan 2, 2020 |
| Split Type | backward |
| Split Ratio | 1:300 |
Scores
| Altman Z-Score | -38.2 |
| Piotroski F-Score | 2 |